-+ 0.00%
-+ 0.00%
-+ 0.00%

INNOCARE ANNOUNCES PHASE II STUDY RESULTS OF TYK2 INHIBITOR SOFICITINIB MEET PRIMARY ENDPOINT IN PATIENTS WITH VITILIGO

路透·07/16/2026 13:00:02

登錄查看新聞詳情